CT Imaging Features of 2019 Novel Coronavirus                    (2019-nCoV)

Chung, Michael; Bernheim, Adam; Mei, Xueyan; Zhang, Ning; Huang, Mingqian; Zeng, Xiaoyang; Cui, Jiufa; Xu, Wenjian; Yang, Ya; Fayad, Zahi A.; Jacobi, Adam; Li, Kunwei; Li, Shaolin; Shan, Hong

doi:10.1148/radiol.2020200230

Cited by 2,550 publications

(2,801 citation statements)

References 8 publications

Supporting

220

Mentioning

2,352

Contrasting

Unclassified

101

Order By: Relevance

“…In the chest HRCT manifestations patients in this study, patchy GGO and consolidation were common features. Similar manifestations were also present in severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) infections, as shown in previous studies [8][9] . In this study, the lesions of patients were mainly located in the lower lobe of the right lung.…”

Section: Covid-19 Infection and Distinguished Imaging Signs Between Psupporting

confidence: 83%

High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages

Chen

Fan

Cai

et al. 2020

European Journal of Radiology

106

View full text Add to dashboard Cite

Highlights:GGO with crazy-paving patterns or interlobular septa thickening were common signs Fewer lesions were identified in the younger and adolescent age groups Distribution of lesions in the lungs showed age-related differences ABSTRACT J o u r n a l P r e -p r o o f Purpose: We aimed to compare chest HRCT lung signs identified in scans of differently aged patients with COVID-19 infections. Methods: Case data of patients diagnosed with COVID-19 infection in Hangzhou City, Zhejiang Province in China were collected, and chest HRCT signs of infected patients in four age groups (<18 years, 18-44 years, 45-59 years, ≥60 years) were compared.Results: Small patchy, ground-glass opacity (GGO), and consolidations were the main HRCT signs in 98 patients with confirmed COVID-19 infections. Patients aged 45-59 years and aged ≥60 years had more bilateral lung, lung lobe, and lung field involvement, and greater lesion numbers than patients <18 years. GGO accompanied with the interlobular septa thickening or a crazy-paving pattern, consolidation, and air bronchogram sign were more common in patients aged 45-59 years, and ≥60 years, than in those aged <18 years, and aged 18-44 years. Conclusions:Chest HRCT manifestations in patients with COVID-19 are related to patient's age, and HRCT signs may be milder in younger patients.

show abstract

Section: Covid-19 Infection and Distinguished Imaging Signs Between Psupporting

confidence: 83%

High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages

Chen

Fan

Cai

et al. 2020

European Journal of Radiology

106

View full text Add to dashboard Cite

show abstract

“…Each of the five lung lobes was assessed for degree of involvement and classified as none (0%), minimal (1 -25%), mild (26 -50%), moderate (51 -75%), or severe (76 -100%). None corresponded to a lobe score of 0, minimal to a lobe score of 1, mild to a lobe score of 2, moderate to a lobe score of 3, and severe to a lobe score of 4 [9,10]. 5(31%) of 16 patients reached a lobe score of 4 in the combination group and 6(35%) of 17 in the monotherapy group in baseline characteristics, and there is no statistically significant differences between two groups (Table 1).…”

Section: Resultsmentioning

confidence: 99%

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study

Deng

Zeng

et al. 2020

Journal of Infection

464

463

View full text Add to dashboard Cite

Highlights Patients were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5-21 days  Our study shows that oral arbidol and LPV/r in the combination group is associated with a significant elevated negative conversion rate of coronavirus' test in 7-day and 14-day, compared with LPV/r only in the monotherapy group. Combination therapy is associated with a significantly improved the chest CT scans in 7-day. We suppose that reducing the viral load as soon as possible could benefit the delay of the progression of lung lesions. Abstract BackgroundCorona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only. MethodsIn this retrospective cohort study, we included adults (age≥18years) with laboratory-confirmed COVID-19 without Invasive ventilation, diagnosed between Jan 17, 2020, and Feb 13, 2020. Patients, diagnosed after Jan 17, 2020, were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5-21 days. The primary endpoint was a negative conversion rate of coronavirus from the date of COVID-19 diagnosis(day7, day14), and assessed whether the pneumonia was progressing or improving by chest CT (day7). ResultsWe analyzed 16 patients who received oral arbidol and LPV/r in the combination group and 17 who oral LPV/r only in the monotherapy group, and both initiated after diagnosis. Baseline clinical, laboratory, and chest CT characteristics were similar between groups. The SARS-CoV-2 could not be detected for 12(75%) of 16 patients' nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p<0·05). After 14 days, 15 (94%) of 16 and 9 (52·9%) of 17, respectively, SARS-CoV-2 could not be detected (p<0·05). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p<0·05). ConclusionIn patients with COVID-19, the apparent favorable clinical response with arbidol and LPV/r supports further LPV/r only.

show abstract

“…More than 75% of patients presented with bilateral lung involvement [4 , 5 , 8 , 32] , and multilobe involvement was also common (71%) [33] . Ground-glass opacity (GGO) was the most common finding from chest computed tomography (CT) [8 , 34] , and in a series of 21 patients, 86% had GGO on chest CT and 29% showed consolidation [33] . Approximately one-third of patients showed a peripheral distribution of GGO.…”

Section: Imagingmentioning

confidence: 99%

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Lai

Shih

et al. 2020

International Journal of Antimicrobial Agents

5,290

4,340

View full text Add to dashboard Cite

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Cited by 2,550 publications

References 8 publications

High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages

High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Contact Info

Product

Resources

About